Lazaros I. Sakkas

Prof. Lazaros I. Sakkas

Department of Rheumatology and clinical Immunology, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2016 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
AMAthanasios Mavropoulos
Athanasios Mavropoulos
TSTheodora Simopoulou
Theodora Simopoulou
AVAreti Varna
Areti Varna
CLChristos Liaskos
Christos Liaskos
CKChristina G Katsiari
Christina G Katsiari
LSLazaros I. Sakkas
Lazaros I. Sakkas

1 December 2006 in Nature Clinical Practice Rheumatology
Verified
Journal Article
Closed access
PDF file
LSLazaros I. Sakkas
Lazaros I. Sakkas
ICIan C Chikanza
Ian C Chikanza
CPChris D Platsoucas
Chris D Platsoucas

26 May 2010 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
EZElias Zintzaras
Elias Zintzaras
IAIoannis Alexiou
Ioannis Alexiou
APAphrodite A Papathanasiou
Aphrodite A Papathanasiou
EDEvangelos Davas
Evangelos Davas
LSLazaros I. Sakkas
Lazaros I. Sakkas
Background: Rheumatic diseases are a major health and financial burden for societies. The prevalence of rheumatic diseases may change over time, and therefore, we sought to estimate the prevalence of rheumatic diseases in an adult population of central Greece. Methods: In this prospective cross-sectional population survey, a random sample of adult population was drawn from poll catalogues of a region in central Greece. A postal questionnaire was sent to 3,528 people for the presence of any rheumatic disease. All positive cases were further confirmed by clinical examination using the American College of Rheumatoloy criteria. Multiple regression analysis was used to assess risk factors for rheumatic diseases. Results: The response rate was 48.3% (1,705 answers). Four hundred and twenty individuals (24.6%) had a rheumatic disease. The prevalence of rheumatoid arthritis was 0.58% (95% confidence interval [CI], 0.32-0.87), of psoriatic arthritis was 0.35% (95% CI, 0.33-1.13), of ankylosing spondylitis was 0.29% (95% CI, 0.28-0.94), of primary Sjögren's syndrome was 0.23% (95% CI, 0.22-0.75) and of systemic lupus erythematosus was 0.11% (95% CI, 0.11-0.37). One individual had systemic sclerosis (prevalence, 0.058%), 1 individual had dermatomyositis (prevalence, 0.058%; 95% CI, 0.05-0.18), 2 individuals had vasculitis (prevalence 0.11%; 95% CI, 0.11-0.37), 81 individuals had gout (prevalence, 4.75%; 95% CI, 4.41-5.13), and 304 individuals had osteoarthritis (OA) (prevalence 17.82%; 95% CI, 16.50-19.34). Gout was associated with male gender, diabetes mellitus, and hypertension, and OA was associated with age, female gender, and hypertension. Conclusions: Rheumatic diseases are common in central Greece, affecting nearly a quarter of adult population. OA and gout are the most common joint disorders.

1 November 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
LSLazaros I. Sakkas
Lazaros I. Sakkas
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
CKChristina G Katsiari
Christina G Katsiari
CPChris D. Platsoucas
Chris D. Platsoucas

12 September 2013 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
AMAthanasios Mavropoulos
Athanasios Mavropoulos
EREirini I. Rigopoulou
Eirini I. Rigopoulou
CLChristos Liaskos
Christos Liaskos
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
LSLazaros I. Sakkas
Lazaros I. Sakkas
The pathogenetic mechanisms responsible for the induction of immune-mediated disorders, such as psoriasis, remain not well characterized. Molecular signaling pathways are not well described in psoriasis, as well as psoriatic arthritis, which is seen in up to 40% of patients with psoriasis. Signaling pathway defects have long been hypothesized to participate in the pathology of psoriasis, yet their implication in the altered psoriatic gene expression still remains unclear. Emerging data suggest a potential pathogenic role for mitogen activated protein kinases p38 (p38 MAPK) extracellular signal-regulated kinase 1/2 (ERK1/2), and c-Jun N-terminal kinase (JNK) in the development of psoriasis. The data are still limited, though, for psoriatic arthritis. This review discusses the current data suggesting a crucial role for p38 MAPK in the pathogenesis of these disorders.

1 August 2005 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
AKA Kalogerou
A Kalogerou
EGE Gelou
E Gelou
SMS Mountantonakis
S Mountantonakis
LSL Settas
L Settas
EZEfterpi Zafiriou
Efterpi Zafiriou
LSLazaros I. Sakkas
Lazaros I. Sakkas
Objectives: To determine if T cells in skin lesions in systemic sclerosis (SSc) express the early activation antigen CD69 that participates in cell-cell interactions. Methods: Skin biopsy specimens from 17 patients with SSc were analysed by immunohistochemistry using the indirect peroxidase method and monoclonal antibodies for CD3 (T cell marker), CD69 (early T cell activation marker), and CD68 (macrophage marker). Results: Mononuclear cells, containing mostly T cells and macrophages, were increased in SSc skin lesions and were present in perivascular areas. CD69 was expressed in these mononuclear cells. There was no correlation between the number of CD3+, CD69+, or CD68+ cells and the Rodnan skin score or disease duration. Conclusions: The expression of early T cell activation antigen CD69 in skin lesions suggests that T cells may actively participate in cell-cell contact with fibroblasts to promote fibrosis.